# MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

> **NCT03321981** · PHASE2 · COMPLETED · sponsor: **Merus B.V.** · enrollment: 105 (actual)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Zenocutuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Vinorelbine
- **DRUG:** Endocrine therapy

## Key facts

- **NCT ID:** NCT03321981
- **Lead sponsor:** Merus B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-15
- **Primary completion:** 2022-10-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03321981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03321981, "MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03321981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*